CervoMed is trading -6.03% at $1.65, with no new company-specific catalyst clearly explaining the October 30 decline.
- An October 29 research-publication announcement noted that the Phase 2b RewinD-LB trial missed its primary endpoint in the overall study population, though subgroup and imaging findings were supportive. Reports do not establish that news as the cause of today’s move.
- Healthcare was reported up 2.32% during the regular session. Shares had already fallen 20.81% on October 29, per external reporting.